Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a distinct subtype of T
lymphoblastic leukemia (T-ALL) identified in 2009, due to its unique immunophenotypic and …

Chimeric antigen receptor T-cell therapy (CAR-T) targeting CD19 has been associated with
remarkable responses in paediatric patients and adolescents and young adults (AYA) with …

Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy resulting
from overproduction of immature T-cells in the thymus and is typified by widespread …

An updated strategy combining pediatric-based chemotherapy with risk-oriented allogeneic
hematopoietic cell transplantation (HCT) was evaluated in Philadelphia chromosome …

Unlike chimeric antigen receptors, T-cell receptors (TCRs) can recognize intracellular
targets presented on human leukocyte antigen (HLA) molecules. Here we demonstrate that …

T cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive malignancy of
progenitor T cells. Despite significant improvements in survival of T-ALL/LBL over the past …

Pediatric acute lymphoblastic leukemia generally carries a good prognosis, and most
children will be cured and become long-term survivors. However, a portion of children will …

T-cell malignancies can be divided into precursor (T-acute lymphoblastic leukemia/
lymphoblastic lymphoma, T-ALL/LBL) and mature T-cell neoplasms, which are comprised of …

With recent prospective clinical trials that used paediatric regimens with multiple doses of
pegylated form of asparaginase (PEG asparaginase) in adults reporting significantly …

Administration of pediatric-inspired chemotherapy to adults up to age 60 with acute
lymphoblastic leukemia (ALL) is challenging in part due to toxicities of asparaginase as well …